A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers.

ABSTRACT:

Objectives

A phase II trial designed to evaluate the safety and efficacy of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine or epithelial ovarian cancers.

Methods

Eligible patients with recurrent epithelial ovarian or uterine cancers were treated with weekly topotecan 3.5 mg/m(2) and docetaxel 30 mg/m(2) for 3 consecutive weeks. Cycles were repeated every 4 weeks for 6 cycles or until evidence of disease progression, unacceptable toxicity, or death. Response was assessed as per RECIST or Rustin's criteria. Time to best response and overall survival were calculated using Kaplan-Meier statistical methods.

Results

Twenty-seven patients registered, of which 24 were evaluable for response. The majority of patients had received 2 prior chem

SUBMITTER: Gupta D 

PROVIDER: S-EPMC4451225 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature